Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- BIOPOR.CO
- Price
- 1.01
- Stock movement up
- +0.01 (1.40%)
- Company name
- BioPorto
- Exchange
- (CO ,
- Currency
- DKK )
- Sector
- Healthcare >Diagnostics & Research
- Market cap
- 502.03M
- Ent value
- 508.85M
- Price/Sales
- 13.73
- Price/Book
- 14.27
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -13.54%
- 1 year return (CAGR)
- -31.49%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
DIVIDENDS
BIOPOR.CO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 13.73 |
| Price to Book | 14.27 |
| EV to Sales | 13.92 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 495.10M |
| EPS (TTM) | -0.19 |
| FCF per share (TTM) | -0.18 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 36.56M |
| Gross profit (TTM) | 23.36M |
| Operating income (TTM) | -93.38M |
| Net income (TTM) | -86.80M |
| EPS (TTM) | -0.19 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 63.90% |
| Operating margin (TTM) | -255.40% |
| Profit margin (TTM) | -237.40% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.08M |
| Net receivables | 10.73M |
| Total current assets | 53.48M |
| Goodwill | 0.00 |
| Intangible assets | 173.00K |
| Property, plant and equipment | 6.90M |
| Total assets | 68.09M |
| Accounts payable | 5.23M |
| Short/Current long term debt | 8.34M |
| Total current liabilities | 27.97M |
| Total liabilities | 32.91M |
| Shareholder's equity | 35.18M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -78.91M |
| Capital expenditures (TTM) | 1.37M |
| Free cash flow (TTM) | -80.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -246.71% |
| Return on Assets | -127.47% |
| Return on Invested Capital | -246.71% |
| Cash Return on Invested Capital | -228.17% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.00 |
| Daily high | 1.03 |
| Daily low | 0.98 |
| Daily Volume | 380K |
| All-time high | 16.39 |
| 1y analyst estimate | - |
| Beta | 1.31 |
| EPS (TTM) | -0.19 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| BIOPOR.CO | S&P500 | |
| Current price drop from All-time high | -93.81% | -0.89% |
| Highest price drop | -93.90% | -19.00% |
| Date of highest drop | 21 Jan 2026 | 8 Apr 2025 |
| Avg drop from high | -91.39% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 320 days | 89 days |
COMPANY DETAILS
Marketcap
502.03M
Marketcap category
Small-cap
Description
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.
Employees
48
Website
Investor relations
-
SEC filings
CEO
Country
Denmark
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSW...
February 5, 2026
December 11, 2025 Announcement no. 29 Changes to the Executive Management COPENHAGEN, DENMARK and BOSTON, MA, USA, December 11, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto”) (CPH:BIOPOR) announced...
December 11, 2025
November 24, 2025Announcement no. 28 Managers’ transactions In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 27, BioPorto A/S has received not...
November 24, 2025
24 November 2025 Announcement no. 27 BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes Completion of share capital increase COPENHAGEN, DENMA...
November 24, 2025
November 19, 2025 Announcement no. 26 BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth. Copenhagen, Denmark, November 19, 2025, (GLOBE NEWSWIR...
November 19, 2025
13 November 2025 Announcement no. 25 Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S Copenhagen, Denmark, 13 November 2025,...
November 13, 2025
BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement
13 November 2025 Announcement no. 24 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOU...
November 13, 2025
November 4, 2025Announcement no. 23 Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – B...
November 4, 2025
November 4, 2025 Announcement no. 22 Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPor...
November 4, 2025
November 4, 2025Announcement no. 21 Progress Update on BioPorto’s Adult Clinical Study Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR)...
November 4, 2025
Next page